The estimated Net Worth of Trevor Hallam is at least $1.6 Million dollars as of 14 April 2023. Trevor Hallam owns over 3,750 units of Sutro Biopharma Inc stock worth over $468,671 and over the last 20 years he sold STRO stock worth over $104,276. In addition, he makes $1,031,080 as Chief Scientific Officer at Sutro Biopharma Inc.
Sign up
Trevor Hallam STRO stock SEC Form 4 insiders trading
Trevor has made over 30 trades of the Sutro Biopharma Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 3,750 units of STRO stock worth $17,288 on 14 April 2023.
The largest trade he's ever made was exercising 300,000 units of Sutro Biopharma Inc stock on 26 March 2010 worth over $1,383,000. On average, Trevor trades about 16,758 units every 148 days since 2005. As of 14 April 2023 he still owns at least 101,664 units of Sutro Biopharma Inc stock.
You can see the complete history of Trevor Hallam stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Trevor Hallam biography
Dr. Trevor Hallam, Ph.D. is Chief Scientific Officer of the Company. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, SmithKline & French Laboratories, Ltd., Glaxo Group Research Ltd., Roche Research and Rhone-Poulenc Rorer. Dr. Hallam received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.
What is the salary of Trevor Hallam?
As the Chief Scientific Officer of Sutro Biopharma Inc, the total compensation of Trevor Hallam at Sutro Biopharma Inc is $1,031,080. There are 2 executives at Sutro Biopharma Inc getting paid more, with William Newell having the highest compensation of $3,817,120.
How old is Trevor Hallam?
Trevor Hallam is 61, he's been the Chief Scientific Officer of Sutro Biopharma Inc since 2010. There are 16 older and 3 younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
What's Trevor Hallam's mailing address?
Trevor's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Sutro Biopharma Inc
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund, and Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
What does Sutro Biopharma Inc do?
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
What does Sutro Biopharma Inc's logo look like?
Complete history of Trevor Hallam stock trades at Palatin Technologies and Sutro Biopharma Inc
Sutro Biopharma Inc executives and stock owners
Sutro Biopharma Inc executives and other stock owners filed with the SEC include:
-
William Newell,
Chief Executive Officer, Director -
William J. Newell J.D.,
CEO & Director -
Trevor Hallam,
Chief Scientific Officer -
Arturo Molina,
Chief Medical Officer -
William J. Newell,
CEO & Director -
Jane Chung R.Ph.,
Chief Commercial Officer -
Dr. Trevor J. Hallam,
Pres of Research & Chief Scientific Officer -
Linda A. Fitzpatrick,
Chief People & Communications Officer -
Connie Matsui,
Chairman of the Board -
Shalini Sharp,
Independent Director -
Joseph Lobacki,
Independent Director -
Michael Dybbs,
Independent Director -
John Freund,
Independent Director -
Daniel Petree,
Director -
Annie Chang,
Head of Investor Relations -
Diana Landa,
Vice President of Regulatory Affairs -
James Panek,
Director -
Shabbir Anik,
Chief Technical Operations Officer -
Brunilda Shtylla,
Vice President - Business Development -
Craig Berman,
Vice President - Clinical Development -
Kristin Bedard,
Vice President - Immunobiology -
Carlos Lugo,
Vice President - Quality and CMC Regulatory Operations -
Regina Cheng,
Vice President - Finance, Controller -
Linda Fitzpatrick,
Chief People and Communications Officer -
Edward Albini,
Chief Financial Officer -
Dr. James R. Swartz Ph.D., Sc.D.,
Founder -
Dr. Arturo M. Molina FACP, M.D., MS,
Chief Medical Officer -
Annie J. Chang M.B.A.,
VP of Investor Relations -
Dr. Arturo M. Molina,
Chief Medical Officer -
Dr. Nicki Vasquez Ph.D.,
Chief Portfolio Strategy & Alliance Officer -
David Pauling J.D., M.A.,
Gen. Counsel -
Dr. Shabbir T. Anik,
Chief Technical Operations Officer -
Edward C. Albini,
CFO & Sec. -
Dr. James R. Swartz,
Founder and Member of Scientific Advisory Board -
Nicki Vasquez,
CHIEF PORT. STRAT & ALNCE OFCR -
Corp /De/ Celgene,
-
Michael Jay Ross,
Director -
Partners Viii, L.P.Alta Par...,
-
V Bryan Lawlis,
Director -
Daniel Janney,
Director -
Stephen Worsley,
Chief Business Officer -
& Co., Inc.Merck Sharp & Do...,
-
Venture Partners V Lp Skyli...,
-
V, Llcilsf Iii, Llcinternat...,
-
Jane Chung,
PRESIDENT AND COO -
Venkatesh Srinivasan,
CHIEF TECH OP OFFICER -
Anne Elizabeth Borgman,
CHIEF MEDICAL OFFICER -
Sukhi Jagpal,
-
Hans Peter Gerber,
CHIEF SCIENTIFIC OFFICER -
Heidi Hunter,
-
Jon Marc Wigginton,
-
Barbara Leyman,
Chief Business Dev. Officer